Dapagliflozin lowers plasma glucose concentration and improves β-cell function.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Beta-cell dysfunction is central to type 2 diabetes (T2DM).
• Chronic hyperglycemia (glucotoxicity) contributes to progressive beta-cell failure.
• Investigating glucose-lowering agents' impact on beta-cell function is crucial.

Purpose of the Study:

• To assess the effect of dapagliflozin, a glucosuric agent, on beta-cell function in T2DM patients.
• To determine if reducing plasma glucose levels with dapagliflozin can mitigate glucotoxicity.
• To evaluate changes in insulin sensitivity and beta-cell function parameters.

Main Methods:

• A 2-week randomized controlled trial involving 24 T2DM subjects.
• Treatment groups: dapagliflozin (n=16) and placebo (n=8).
• Evaluations included oral glucose tolerance tests (OGTT) and insulin clamp studies before and after treatment.

Main Results:

• Dapagliflozin significantly reduced fasting and 2-hour plasma glucose levels during OGTT.
• The ratio of C-peptide to glucose change (ΔC-Pep0-120/ΔG0-120), an indicator of beta-cell function, significantly increased with dapagliflozin.
• Whole-body insulin sensitivity improved significantly in the dapagliflozin group.
• Overall beta-cell function, adjusted for insulin resistance, showed a 2-fold increase with dapagliflozin compared to placebo.

Conclusions:

• Lowering plasma glucose with dapagliflozin markedly improves beta-cell function in T2DM.
• These findings provide strong clinical evidence for the detrimental glucotoxic effect of hyperglycemia on beta-cell function.
• Dapagliflozin represents a therapeutic strategy to enhance beta-cell function in T2DM by addressing glucotoxicity.